Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 13/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16926802 | 1.00 | BTN3A1 (0.69) | BTN3A1LMNATDP1MEN1KMT2A | |
| SCHEMBL18801782 | 1.00 | BTN3A1 (0.69) | BTN3A1LMNATDP1MEN1KMT2A | |
| SCHEMBL13522954 | 1.00 | BTN3A1 (0.69) | BTN3A1LMNATDP1MEN1KMT2A | |
| SCHEMBL16587319 | 1.00 | BTN3A1 (0.69) | BTN3A1LMNATDP1MEN1KMT2A | |
| SCHEMBL16587334 | 0.92 | BTN3A1 (0.66) | BTN3A1LMNATDP1MEN1KMT2A | |
| SCHEMBL16587332 | 0.92 | BTN3A1 (0.66) | BTN3A1LMNATDP1MEN1KMT2A | |
| SCHEMBL16587337 | 0.92 | BTN3A1 (0.66) | BTN3A1LMNATDP1MEN1KMT2A | |
| SCHEMBL16587333 | 0.92 | BTN3A1 (0.66) | BTN3A1LMNATDP1MEN1KMT2A | |
| SCHEMBL18801992 | 0.92 | BTN3A1 (0.66) | BTN3A1LMNATDP1MEN1KMT2A | |
| SCHEMBL14042804 | 0.92 | BTN3A1 (0.66) | BTN3A1LMNATDP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024107859-A1 | CYCLOPENTENE-OXYMETHYLENE PHOSPHONAMIDATES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | ROME THERAPEUTICS, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-10196419-B2 | Processes and intermediates for preparing anti-HIV agents | GILEAD SCIENCES, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20180079773-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING ANTI-HIV AGENTS | GILEAD SCIENCES, INC. | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196419-B2 | Processes and intermediates for preparing anti-HIV agents | SAMHD1, DHPS, LSS | BTN3A1 4464/4885LMNA 1511/4885TDP1 1786/4885 |
| US-20180079773-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING ANTI-HIV AGENTS | SAMHD1, DHPS, LSS | BTN3A1 4464/4885LMNA 1511/4885TDP1 1786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.